The prevention and treatment of progressing stroke should be one of the main therapeutic targets of neuroprotective therapies. Despite the high prevalence of progressing stroke in acute stroke (25–35%) and its importance as a predictor of poor outcome, no treatment capable of preventing early neurological deterioration (END) or of reducing its impact has yet been developed. It is essential that our understanding of END’s underlying mechanisms be improved as it is currently not possible to predict its occurrence accurately. Published studies to date have been unable to identify a clinical profile which reliably predicts those patients likely to suffer neurological deterioration in the very early acute phase of ischemic stroke. In the following pages, we will discuss the present situation with regard to neurological worsening in general, paying special attention to END given the prognostic and therapeutic implications of this common condition. Factors associated with neurological deterioration and the potential mechanisms, particularly excitotoxic theory, are discussed.

Keywords:
Progressing stroke, Early neurological deterioration, Glutamate, Excitotoxicity, Acute ischemic stroke
1.
Jones HJ, Millikan CH: Temporal profile (clinical course) of acute carotid system cerebral infarction. Stroke 1976;7:64–71.
2.
Patrick BK, Ramirez-Lassepas M, Synder BD: Temporal profile of vertebrobasilar territory infarction. Prognostic implications. Stroke 1980;11:643–648.
3.
Jones HR Jr, Millikan CH, Sandok BA: Temporal profile (clinical course) of acute vertebrobasilar system cerebral infarction. Stroke 1980;11:173–177.
4.
Britton M, Roden A: Progression of stroke after arrival at hospital. Stroke 1985;16:629–632.
5.
Lodder J, Gorsselink EL: Progressive stroke caused by CT-verified small deep infarcts; relation with the size of the infarct and clinical outcome. Acta Neurol Scand 1985;71:328–330.
6.
Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS: Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344:156–159.
7.
Toni D, Fiorelli M, Gentile M, Bastianello S, Sacchetti ML, Argentino C, Pozzilli C, Fieschi C: Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis. Arch Neurol 1995;52:670–675.
8.
Dávalos A, Castillo J, Pumar JM, Noya M: Body temperature and fibrinogen are related to early neurological deterioration in acute ischemic stroke. Cerebrovasc Dis 1997;7:64–69.
9.
Hachinski V, Norris JW: The deteriorating stroke; in Meyer JS Lechner H, Reivich M, Ott EO, Aranibar A (eds): 10th International Salzburg Conference on Cerebral Vascular Disease, Salzburg, Sept 1980. Amsterdam, Excerpta Medica, 1980, pp 315–318.
10.
Davalos A, Cendra E, Teruel J, Martinez M, Genis D: Deteriorating ischemic stroke: risk factors and prognosis. Neurology 1990;40:1865–1869.
11.
Toni D, Fiorelli M, Zanette EM, Sacchetti ML, Salerno A, Argentino C, Solaro M, Fieschi C: Early spontaneous improvement and deterioration of ischemic stroke patients. A serial study with transcranial Doppler ultrasonography. Stroke 1998;29:1144–1148.
12.
Yamamoto, H, Bogousslavsky J, van Melle G: Different predictors of neurological worsening in different causes of stroke. Arch Neurol 1998;55:481–486.
13.
Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A: Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004;35:520–527.
14.
Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J for the ECASS Group: Neurological deterioration in acute ischemic stroke. Potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke 1999;30:2631–2636.
15.
Serena J, Leira R, Castillo, Pumar JM, Castellanos M, Dávalos A: Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke 2001;32:1154–1161.
16.
Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A: Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002;33:982–987.
17.
Leira R, Dávalos A, Aneiros A, Serena J, Pumar JM, Castillo J: Headache as a surrogate marker of the molecular mechanisms implicated in progressing stroke. Cephalalgia 2002;22:303–308.
18.
Millikan CH, Siekert RG: Studies in cerebrovascular disease. I. The syndrome of intermittent insufficiency of the basilar arterial system. Mayo Clin Proc 1955;30:61–68.
19.
Castillo J: Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment.Cerebrovasc Dis 1999;9(suppl 3):1–8.
20.
Nakamura K, Saku Y, Ibayashi S, Fujishima M: Progressive motor deficits in lacunar infarction. Neurology 1999;52:29–33.
21.
Castillo J, Rama R, Dávalos A: Nitric oxide-related brain damage in acute ischemic stroke. Stroke 2000;31:852–857.
22.
Castillo J, Dávalos A, Noya M: Progression of ischemic stroke and excitotoxic amino acids. Lancet 1997;349:79–83.
23.
Dávalos A, Castillo J, Marrugat J, Fernández-Real JM, Armengou A, Cacabelos P, Rama R: Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology 2000;54:1568–1574.
24.
Berger L, Hakim AM: The association of hyperglycemia with cerebral edema in stroke. Stroke 1986;17:865–871.
25.
Toni D, De Michele M, Fiorelli M, Bastianello S, Camerlingo M, Sacchetti ML, Argentino C, Fieschi C: Influence of hyperglycaemia on infarct size and clinical outcome of acute ischemic stroke patients with intracranial arterial occlusion. J Neurol Sci1994;123:129–133.
26.
Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, McMahan MR, Thompson CJ, Heiss G, Crouse JR: Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case-control study. Circulation 1990;82:1230–1242.
27.
Derdeyn CP, Grubb RL, Powers WJ: Cerebral hemodynamic impairment. Methods of measurement and association with stroke risk. Neurology 1999;53:251–259.
28.
Kaps M, Teschendorf U, Dorndorf W: Hemodynamic studies in early stroke. J Neurol 1992;239:138–142.
29.
Rubin G, Firlik A, Levy E, Pindzola R, Yonas H: Relationship between cerebral blood flow and clinical outcome in acute stroke. Cerebrovasc Dis2000;10:298–306.
30.
Alexandrov AV, Demchuk A, Wein T, Grotta JC: The yield of transcranial Doppler in acute cerebral ischemia. Stroke 1999;30:1604–1609.
31.
Ðlvarez FJ, Segura T, Castellanos M, Leira R, Blanco M, Dávalos A, Serena J: Cerebral hemodynamic reserve and early neurologic deterioration in acute ischemic stroke. J Cereb Blood Flow Metab 2004:2004;24:1267–1271.
32.
Ringelstein EB, Sievers C, Ecker S, Schneider PA, Otis SM: Noninvasive assessment of CO2-induced cerebral vasomotor response in normal individuals and patients with internal carotid artery occlusions. Stroke 1998;19:963–969.
33.
Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Dávalos A: The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005;36:1921–1926.
34.
De Cristobal J, Moro MA, Davalos A, Castillo J, Leza JC, Camarero J, Colado MI, Lorenzo P, Lizasoain I: Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischaemia in rats. J Neurochem 2001;79:456–459.
35.
Castillo J, Leira R, Moro MA, Lizasoain I, Serena J, Dávalos A: Neuroprotective effects of aspirin in patients with acute cerebral infarction. Neurosci Lett 2003;339:248–250.
36.
Grotta JC, Lemak NA, Gary H, Fields WS, Vital D: Does platelet antiaggregant therapy lessen the severity of stroke? Neurology 1985;35:632–636.
37.
Takagi K, Ginsberg MD, Globuls MYT, Dietrich WD, Martinez E, Kraydieh S, Busto R: Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbra region following middle cerebral artery occlusion in the rat: correlation with histopathology. J Cereb Blood Flow Metab 1993;13:575–585.
38.
Butcher SP, Bullock R, Graham DI, McCulloch J: Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke1990;21:1727–1733.
39.
Dávalos A, Castillo J, Serena J, Noya M: Duration of glutamate release after acute ischemic stroke. Stroke 1997;28:708–710.
40.
Dávalos A, Castillo J: Potential mechanisms of worsening. Cerebrovasc Dis 1997;7(suppl 5): 19–24.
41.
Rothman SM, Olney JW: Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105–111.
42.
Castillo J, Leira R: Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms. Would its early treatment be useful?Cerebrovasc Dis 2001;11(suppl 1):40–48.
43.
Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci1999;22:391–397.
44.
Castillo J, Davalos A, Naveiro J, Noya M: Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke1996;27:1060–1065.
45.
Castillo J, Dávalos A, Lema M, Serena J, Noya M: Glutamate is a marker for cerebral ischemia in cortical but not deep infarcts. Cerebrovasc Dis 1997;7:245–250.
46.
Castellanos M, Blanco M, Pedraza S, García M, Silva Y, Leira R, Dávalos A: Molecular markers of progressing stroke are associated with diffusion-weighted MRI lesion growth in patients with acute ischemic stroke. Stroke 2004;35:247.
47.
Seal RP, Amara SG: Excitatory amino acid transporters: a family in flux. Annu Rev Pharmacol Toxicol 1999;39:431–456.
48.
Mallolas J, Hurtado O, Castellanos M, Blanco M, Rodríguez-Yáñez M, Puigdemont M, Serena J, Pedraza S, Moro MA, Lizasoain I, Castillo J, Davalos A: A novel functional polymorphism in the EAAT2 gene is associated with higher glutamate concentrations and brain injury. Stroke 2005;36:458.
49.
Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A: Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003;34:671–675.
50.
Blanco M, Moro MA, Dávalos A, Leira R, Castellanos M, Serena J, Vivancos J, Rodríguez-Yáñez M, Lizasoain I, Castillo J: Increased plasma levels of 15-deoxy δ prostaglandin j2 are associated with good outcome in acute atherothrombotic ischemic stroke. Stroke 2005;36:1189–1194.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.